MCID: CRV038
MIFTS: 60

Cervical Squamous Cell Carcinoma malady

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

Aliases & Descriptions for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 38 12 56 52 14 69
Squamous Cell Carcinoma of the Cervix Uteri 12 56
Squamous Cell Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3744
NCIt 47 C4028
SNOMED-CT 64 254886006
Orphanet 56 ORPHA213767
ICD10 via Orphanet 34 C53.0 C53.1 C53.8
UMLS 69 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology : 12 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary : Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to microinvasive cervical squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Ethanol and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and lymph node, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
id Related Disease Score Top Affiliating Genes
1 microinvasive cervical squamous cell carcinoma 12.2
2 cervical intraepithelial neoplasia 11.4
3 cervicitis 10.9
4 squamous cell carcinoma 10.9
5 clear cell adenofibroma 10.3 CDKN2A TP53
6 linitis plastica 10.3 CDH1 TP53
7 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
8 aml with myelodysplasia-related features 10.3 CDKN2A MKI67 TP63
9 spondylarthropathy 10.3 CDKN2A MKI67 TP53
10 oro-mandibular-limb hypogenesis syndrome 10.3 CDKN2A MKI67 TP53
11 pericardium leiomyoma 10.3 CDKN2A TP53
12 wolffian adnexal neoplasm 10.3 EGFR MKI67 TP53
13 mitochondrial encephalomyopathy 10.2 CDKN2A TP53 TP63
14 spastic paraplegia 1 10.2 EGFR MKI67 TP53
15 myxedema 10.2 CDKN2A EGFR TP53
16 endometrial squamous cell carcinoma 10.2 CDKN2A RASSF1 TP53
17 allergic contact dermatitis 10.2 CDKN2A EGFR TP53
18 sengers syndrome 10.2 CDH1 CDKN2A EGFR
19 vascular myelopathy 10.2 CDKN2A SOX2 TP53
20 interstitial lung disease 10.2 CDKN2A EGFR TP53
21 maxillary sinus cholesteatoma 10.2 CDH1 CDKN2A TP53
22 coccidiosis 10.2 CDKN2A SERPINB3 TP53
23 plasmodium ovale malaria 10.2 CDKN2A MKI67 TP53 TP63
24 intermediate malignant teratoma 10.2 CDKN2A EGFR SERPINB3
25 cervical verrucous carcinoma 10.2 CDKN2A TP53 TYMP
26 dental caries 10.2 CDH1 EGFR TP53
27 marginal zone b-cell lymphoma 10.2 CDKN2A EGFR TP53
28 fallopian tube adenocarcinoma 10.2 CDKN2A RASSF1 TP53
29 nasal cavity disease 10.2 CDH1 EGFR TP53
30 lacrimal gland squamous cell carcinoma 10.2 CDKN2A KRT8 TP53
31 placental site trophoblastic tumor 10.2 CDKN2A TP53 TYMP
32 his bundle tachycardia 10.2 EGFR MKI67 TP53 TP63
33 post-surgical hypoinsulinemia 10.2 CDKN2A SOX2 TP53
34 estrogen-receptor positive breast cancer 10.2 CDH1 CDKN2A EGFR TP53
35 cleft palate cardiac defect ectrodactyly 10.2 EGFR RASSF1 TP53
36 pyomyositis 10.2 CDH1 CDKN2A EGFR TP53
37 connective tissue benign neoplasm 10.2 CDH1 CDKN2A EGFR TP53
38 occlusion precerebral artery 10.2 CDKN2A EGFR TP53
39 charcot-marie-tooth disease type 2n 10.2 CDKN2A KRT8 MKI67
40 hepatic flexure cancer 10.2 CDKN2A EGFR MKI67 TP53
41 bronchitis 10.2 CDH1 TP53
42 ornithinemia 10.2 CDH1 CDKN2A EGFR TP53
43 scirrhous adenocarcinoma 10.2 CDH1 KRT8 TP63
44 pancreatic cancer 10.2 CDH1 KRT8 TP53
45 gastrointestinal stromal tumor 10.2 CDKN2A EGFR MKI67 TP53
46 ovarian embryonal carcinoma 10.2 EGFR KRT8 TP53
47 nasopharyngeal carcinoma 10.1 CDKN2A EGFR TP53
48 pancreatic cystadenoma 10.1 EGFR SOX2 TP53
49 fallopian tube leiomyosarcoma 10.1 CDH1 CDKN2A DAPK1 TP53
50 immunodeficiency 37 10.1 CDH1 CDKN2A RASSF1

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.47 DAPK1 EGFR
2 Decreased viability GR00221-A-1 9.47 CDH1 CDKN2A DAPK1 EGFR SOX2
3 Decreased viability GR00221-A-3 9.47 CDKN2A
4 Decreased viability GR00221-A-4 9.47 CDKN2A DAPK1 EGFR SOX2
5 Decreased viability GR00301-A 9.47 CDH1
6 Decreased viability GR00342-S-1 9.47 DAPK1

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 KRT8 OSMR RASSF1 CDH1 CDKN2A CTNNB1
2 cellular MP:0005384 10.28 CDH1 CDKN2A CTNNB1 DAPK1 EGFR RASSF1
3 immune system MP:0005387 10.27 CDH1 CDKN2A CTNNB1 EGFR KRT8 OSMR
4 endocrine/exocrine gland MP:0005379 10.19 CDH1 CDKN2A CTNNB1 EGFR OSMR RASSF1
5 digestive/alimentary MP:0005381 10.18 CDH1 CDKN2A CTNNB1 EGFR KRT8 RASSF1
6 embryo MP:0005380 10.11 TP63 CDH1 CDKN2A CTNNB1 EGFR KRT8
7 integument MP:0010771 10.03 CDH1 CDKN2A CTNNB1 EGFR OSMR SOX2
8 liver/biliary system MP:0005370 10.01 CDKN2A CTNNB1 EGFR KRT8 OSMR RASSF1
9 neoplasm MP:0002006 9.97 EGFR RASSF1 SOX2 TP53 TP63 CDH1
10 no phenotypic analysis MP:0003012 9.92 TP53 TP63 CDH1 CDKN2A CTNNB1 EGFR
11 normal MP:0002873 9.86 TP63 CDH1 CTNNB1 EGFR MKI67 RASSF1
12 reproductive system MP:0005389 9.61 CDH1 CDKN2A CTNNB1 EGFR KRT8 SKP2
13 pigmentation MP:0001186 9.55 CDKN2A CTNNB1 EGFR SOX2 TP53
14 respiratory system MP:0005388 9.17 EGFR SERPINB4 SOX2 TP53 TP63 CDKN2A

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 515)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 1 64-17-5 702
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
5
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
6
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9 Titanium dioxide Approved Phase 4 13463-67-7
10
Petrolatum Approved Phase 4 8009-03-8
11
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124 9877265
12 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
13 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Cholinergic Agents Phase 4,Phase 3
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
20 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
27 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
32 Mitomycins Phase 4,Phase 3,Phase 2
33 Adjuvants, Anesthesia Phase 4,Phase 3
34 Narcotics Phase 4,Phase 3,Phase 2
35 Hematinics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Analgesics, Opioid Phase 4,Phase 3,Phase 2
37 Anesthetics Phase 4,Phase 3,Phase 2
38 Anesthetics, General Phase 4,Phase 3
39 Anesthetics, Intravenous Phase 4,Phase 3
40 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
42 mometasone furoate Phase 4 83919-23-7
43 Anti-Allergic Agents Phase 4,Phase 2
44 arginine Nutraceutical Phase 4,Phase 2,Phase 1
45 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2,Phase 1
46
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
47
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
48
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
49
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
50
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 1588)
id Name Status NCT ID Phase
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4
2 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4
3 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4
4 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4
5 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4
6 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4
7 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
8 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
9 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Recruiting NCT02015650 Phase 4
10 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4
11 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4
12 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Active, not recruiting NCT00684385 Phase 4
13 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
14 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4
15 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Not yet recruiting NCT03051516 Phase 4
16 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
17 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
18 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
19 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3
20 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3
21 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
22 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
23 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
24 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3
25 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3
26 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
27 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
28 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3
29 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Unknown status NCT01434394 Phase 2, Phase 3
30 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
31 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3
32 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3
33 Elective or Prophylactic Nodal Irradiation for Esophageal Cancer Unknown status NCT01551589 Phase 3
34 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3
35 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
36 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
37 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
38 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3
39 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3
40 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
41 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3
42 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3
43 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3
44 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3
45 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3
46 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3
47 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3
48 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3
49 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
50 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

39
Uterus, Cervix, Lymph Node, T Cells, Lung, Testes, Placenta

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 308)
id Title Authors Year
1
Chondrosarcoma-like metastasis from a poorly differentiated uterine cervical squamous cell carcinoma. A unique morphology and diagnostic pitfall in cytology. ( 28411397 )
2017
2
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. ( 28526810 )
2017
3
Sulfiredoxin may promote metastasis and invasion of cervical squamous cell carcinoma by epithelial-mesenchymal transition. ( 28351308 )
2017
4
Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. ( 27641506 )
2016
5
Biventricular metastatic invasion from cervical squamous cell carcinoma. ( 27371746 )
2016
6
Prognostic Significance of Cytokeratin 19 and Squamous Cell Cancer Antigen in Histologically Negative Sentinel Lymph Nodes of Cervical Squamous Cell Carcinoma. ( 27654256 )
2016
7
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. ( 26992219 )
2016
8
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. ( 27400321 )
2016
9
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma. ( 27747588 )
2016
10
5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. ( 26851753 )
2016
11
The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy. ( 26807567 )
2016
12
Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. ( 27779103 )
2016
13
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. ( 27431502 )
2016
14
A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass. ( 27695343 )
2016
15
ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women. ( 28036301 )
2016
16
Expression of HIF-2I+ and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance. ( 27413748 )
2016
17
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. ( 27351213 )
2016
18
Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen. ( 27197582 )
2016
19
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. ( 27941992 )
2016
20
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study. ( 27131759 )
2016
21
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. ( 27145272 )
2016
22
Functional significance of transgelin-2 in uterine cervical squamous cell carcinoma. ( 26891454 )
2016
23
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. ( 27087737 )
2016
24
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. ( 27895779 )
2016
25
Involvement of myeloperoxidase gene polymorphism 463G>A in development of cervical squamous cell carcinoma. ( 27197583 )
2016
26
MRI in the synchronic chemoradiotherapy of cervical squamous cell carcinoma. ( 27352568 )
2016
27
Vasculogenic mimicry and hypoxia-inducible factor-1I+ expression in cervical squamous cell carcinoma. ( 26985936 )
2016
28
Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions. ( 27223886 )
2016
29
I9Np63I+ attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. ( 26864590 )
2016
30
Scalp Metastasis as a Presenting Symptom of Cervical Squamous Cell Carcinoma. ( 27105328 )
2016
31
Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. ( 27899965 )
2016
32
A rare case of HPV-negative cervical squamous cell carcinoma. ( 25675193 )
2015
33
Astrocyte elevated gene-1 promotes progression of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition via Wnt signaling. ( 25695541 )
2015
34
The landscape of alternative splicing in cervical squamous cell carcinoma. ( 25565867 )
2015
35
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. ( 26271794 )
2015
36
ALEX1 may be a novel biomarker for human cervical squamous cell carcinoma. ( 26464700 )
2015
37
Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications. ( 26209091 )
2015
38
Expression and significance of LRIG3 in human cervical squamous cell carcinoma. ( 26390694 )
2015
39
[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma]. ( 26978018 )
2015
40
Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy. ( 25773678 )
2015
41
Detection, genotyping and quantitation of multiple hpv infections in south African women with cervical squamous cell carcinoma. ( 26037775 )
2015
42
Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome. ( 26499463 )
2015
43
Prognostic significance of TRAIL signalling molecules in cervical squamous cell carcinoma. ( 26254281 )
2015
44
Immunohistochemical Expression and Prognostic Significance of CD97 and its Ligand DAF in Human Cervical Squamous Cell Carcinoma. ( 26107567 )
2015
45
Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. ( 25434636 )
2015
46
A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. ( 26252302 )
2015
47
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/I^-catenin signaling. ( 26427870 )
2015
48
Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. ( 25586346 )
2015
49
The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. ( 26430661 )
2015
50
An insertion/deletion polymorphism at miRNA-122 binding site in the IL1A is associated with a reduced risk of cervical squamous cell carcinoma. ( 25955681 )
2015

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

9 (show top 50) (show all 53)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 12
2 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 12
3 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 12
4 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 12
5 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 12
6 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 12
7 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 12
8 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 12
9 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 12
10 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 12
11 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 12
12 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 12
13 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 12
14 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 12
15 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 12
16 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 12
17 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 12
18 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 12
19 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 12
20 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 12
21 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 12
22 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 12
23 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 12
24 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 12
25 COSM12459 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1637A>G p.Q546R 12
26 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 12
27 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 12
28 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 12
29 COSM12458 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1634A>C p.E545A 12
30 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 12
31 COSM766 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 12
32 COSM1168056 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 12
33 COSM580 NRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 12
34 COSM120958 NFE2L2 cervix,NS,carcinoma,squamous cell carcinoma c.235G>C p.E79Q 12
35 COSM518 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>C p.G12R 12
36 COSM552 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
37 COSM551 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 12
38 COSM555 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 12
39 COSM517 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
40 COSM521 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>A p.G12D 12
41 COSM499 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 12
42 COSM483 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>T p.G12V 12
43 COSM480 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 12
44 COSM497 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 12
45 COSM715 FGFR3 cervix,NS,carcinoma,squamous cell carcinoma c.746C>G p.S249C 12
46 COSM49175 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.1976A>T p.K659M 12
47 COSM49174 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.289G>A p.A97T 12
48 COSM5731 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.113G>C p.G38A 12
49 COSM5662 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.110C>T p.S37F 12
50 COSM5730 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.122C>A p.T41N 12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

7 (show all 38)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain POLS Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJA5 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain KIAA0947 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCH-VI Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain OSRF Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1, type II Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T-cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4, type II Uterus - 4.45 0.000
6 SPRR3 small proline-rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin-dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine-rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine-rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor, Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C-I Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI Fanconi anemia, complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin, alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13, type I Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1, regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor, type II Uterus - 3.14 0.000
28 CFD complement factor D (adipsin) Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, polyU-specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 CDH1 CDKN2A CTNNB1 EGFR RASSF1 TP53
2 12.31 CDKN2A EGFR RASSF1 TP53 TP63
3 12.3 CDKN2A CTNNB1 HLA-DRB1 TP53
4 12.27 CDKN2A MKI67 SKP2 TP53 TP63
5 12.24 CDH1 CDKN2A SKP2 TP53
6
Show member pathways
12.22 CDH1 CTNNB1 EGFR TP53
7 12.15 CDH1 CDKN2A CTNNB1 DAPK1 EGFR RASSF1
8 12.03 CDH1 CTNNB1 EGFR TP53
9 11.98 CDH1 CTNNB1 RASSF1 SOX2
10 11.97 CDH1 CTNNB1 EGFR TP53
11
Show member pathways
11.74 CDH1 CTNNB1 EGFR
12 11.62 CTNNB1 KRT8 MKI67
13 11.6 CDKN2A CTNNB1 EGFR TP53
14 11.59 CDH1 CTNNB1 EGFR
15 11.49 RASSF1 SKP2 TP53
16 11.41 CDKN2A EGFR TP53
17 11.23 CDH1 CTNNB1 EGFR
18 11.06 CTNNB1 EGFR TP53
19 11.03 CDH1 CDKN2A DAPK1 EGFR RASSF1 TP53
20 10.96 CDH1 CTNNB1 TP53
21 10.71 CDH1 CTNNB1
22
Show member pathways
10.67 CDKN2A TP53 TP63

GO Terms for Cervical Squamous Cell Carcinoma

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CDH1 CDKN2A CTNNB1 DAPK1 DNAJC9 EGFR
2 apical junction complex GO:0043296 9.26 CDH1 CTNNB1
3 catenin complex GO:0016342 9.16 CDH1 CTNNB1
4 flotillin complex GO:0016600 8.96 CDH1 CTNNB1

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.77 CTNNB1 EGFR MKI67 SKP2 TP53
2 single organismal cell-cell adhesion GO:0016337 9.71 CDH1 CTNNB1 EGFR
3 Ras protein signal transduction GO:0007265 9.58 CDKN2A RASSF1 TP53
4 cell cycle arrest GO:0007050 9.56 CDKN2A RASSF1 SOX2 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 TP53 TP63
6 regulation of myelination GO:0031641 9.51 CTNNB1 TYMP
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.49 SOX2 TP63
8 entry of bacterium into host cell GO:0035635 9.48 CDH1 CTNNB1
9 replicative senescence GO:0090399 9.46 CDKN2A TP53
10 mitotic G1 DNA damage checkpoint GO:0031571 9.43 TP53 TP63
11 regulation of apoptotic process GO:0042981 9.35 CTNNB1 DAPK1 SKP2 TP53 TP63
12 protein tetramerization GO:0051262 9.33 HLA-DRB1 TP53 TP63
13 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 CTNNB1
14 positive regulation of transcription, DNA-templated GO:0045893 9.17 CDH1 CDKN2A CTNNB1 EGFR SOX2 TP53

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 SERPINB3 SERPINB4 TP53
2 transcription regulatory region DNA binding GO:0044212 9.26 CTNNB1 SOX2 TP53 TP63
3 protein phosphatase binding GO:0019903 8.8 CTNNB1 EGFR TP53

Sources for Cervical Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....